C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients

Zimmermann, Esther; Anty, Rodolphe; Tordjman, Joan; Verrijken, An; Gual, Philippe; Tran, Albert; Iannelli, Antonio; Gugenheim, Jean; Bédossa, Pierre; Francque, Sven; Marchand-Brustel, Y. Le; Clément, Karine; Gaal, Luc Van; Sørensen, Thorkild I A; Jess, Tine

doi:10.1016/j.jhep.2010.12.017

Cited by 102 publications

(88 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these adipocytokines, leptin, adiponectin, resistin, tumor necrosis factor, and interleukin have been found to be closely related to NAFLD. In addition, hs-CRP is another important inflammatory factor and has been regarded as a pivotal factor that can predict chronic inflammatory reaction, metabolic syndrome, and cardiovascular diseases (14). Adiponectin is one of proteins with high expression in the adipose tissues, which can inhibit inflammation.…”

Section: Discussionmentioning

confidence: 99%

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

Fan¹,

Qin²,

Xu³

et al. 2013

Arq Bras Endocrinol Metab

101

View full text Add to dashboard Cite

Objective: To investigate the effects of exenatide on blood glucose, body weight and hepatic enzymes in patients with type 2 diabetes mellitus (T2DM) and concomitant non-alcoholic fatty liver disease (NAFLD). Subjects and methods: One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group. Patients were treated with exenatide and metformin, respectively, for 12 weeks. Results: After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups. BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group. Conclusion: Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD. Arq Bras Endocrinol Metab. 2013;57(9):702-8 Keywords Exenatide; metformin; non-alcoholic fatty liver disease; type 2 diabetes mellitus RESUMO Objetivo: Investigar os efeitos do exenatide sobre a glicose sérica, peso corporal e enzimas hepá-ticas em pacientes com diabetes melito tipo 2 (T2DM) e doença hepática gordurosa não alcoólica (DHGNA). Sujeitos e métodos: Um total de 117 pacientes com T2DM e DHGNA foi aleatoriamente separado em dois grupos, um tratado com exenatide e um tratado com metformina. Os pacientes foram tratados por 12 semanas. Resultados: Após 12 semanas de tratamento, o peso corporal, índice de massa corporal (IMC), relação cintura-quadril, HbA1c, FPG, glicose pós-prandial, ALT, AST, γ-GT e proteína C-reativa foram significativamente reduzidos, e a relação AST/ALT e a adiponectina aumentaram marcadamente nos dois grupos. O IMC, relação cintura-quadril, glicose pós-prandial, ALT, AST, γ-GT e proteína C-reativa foram marcadamente menores, e a relação AST/ALT e a adiponectina foram dramaticamente mais altas no grupo tratado com exenatide do que no grupo tratado com metformina. Conclusão: Comparado com a metformina, o exenatide controla melhor a glicose sérica, reduz o peso corporal e melhora as enzimas hepáticas, atenuando a DHGNA em pacientes com T2DM de ocorrência concomitante com a DHGNA. Arq Bras Endocrinol Metab. 2013;57(9):702-8 Descritores Exenatide; metformina; doença hepática gordurosa não alcoólica; diabetes melito tipo 2

show abstract

Section: Discussionmentioning

confidence: 99%

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

Fan¹,

Qin²,

Xu³

et al. 2013

Arq Bras Endocrinol Metab

101

View full text Add to dashboard Cite

show abstract

“…However, the role hs-CRP in differentiating severity of NASH remains controversial. Zimmermann et al [40] demonstrated a strong positive association between BMI and hs-CRP levels, which were measured with nephelometry, throughout the broad range of obesity. However, there were no significant associations between inflammation or fibrosis, respectively validation of PTX-3 is warranted to assess the usefulness of PTX-3 in understanding NAFLD.…”

Section: Acute Phase Proteinsmentioning

confidence: 99%

“…The increased production and delayed clearance of hyaluronic acid have been demonstrated to be associated with the severity of hepatic inflammation [56] . Type Ⅳ collagen is the main collagen component of basement membrane whereas laminin is the main non-collagenous glycoproand hs-CRP observed [40] . Serum haemoglobin levels have been observed to be significantly elevated in extremely obese NAFLD patient and shown to be significantly associated with prevalence of NAFLD [41][42][43] .…”

Section: Extracellular Matrixmentioning

confidence: 99%

Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis

Lim

Dillon

Miller

2014

WJG

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a widely prevalent hepatic disorder that covers wide spectrum of liver pathology. NAFLD is strongly associated with liver inflammation, metabolic hyperlipidaemia and insulin resistance. Frequently, NAFLD has been considered as the hepatic manifestation of metabolic syndrome. The pathophysiology of NAFLD has not been fully elucidated. Some patients can remain in the stage of simple steatosis, which generally is a benign condition; whereas others can develop liver inflammation and progress into non-alcoholic steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma. The mechanism behind the progression is still not fully understood. Much ongoing proteomic researches have focused on discovering the unbiased circulating biochemical markers to allow early detection and treatment of NAFLD. Comprehensive genomic studies have also begun to provide new insights into the gene polymorphism to understand patientdisease variations. Therefore, NAFLD is considered a complex and mutifactorial disease phenotype resulting from environmental exposures acting on a susceptible polygenic background. This paper reviewed the current status of proteomic and genomic studies that have contributed to the understanding of NAFLD pathogenesis. For proteomics section, this review highlighted functional proteins that involved in: (1) transportation; (2) metabolic pathway; (3) acute phase reaction; (4) antiinflammatory; (5) extracellular matrix; and (6) immune system. In the genomic studies, this review will discuss genes which involved in: (1) lipolysis; (2) adipokines; and (3) cytokines production. Key words: Non-alcoholic fatty liver disease; Proteomics; Genomics; Metabolic syndrome; Pathophysiology Core tip: Non-alcoholic fatty liver disease (NAFLD) is a widely prevalent hepatic disorder in Western populations. NAFLD can occur as a spectrum diseases, from simple steatosis, to non-alcoholic steatohepatitis characterised by hepatocellular injury and inflammation, to cirrhosis and hepatocellular carcinoma. This paper reviewed the current status of proteomic and genomic studies that have contributed to the understanding of NAFLD pathogenesis. This review highlighted several functional proteins and genetic polymoprhisms; particular those involved in insulin resistance, triglycerides metabolism and hepatic inflammation. It is hoped that this review will offer further insights into the pathophysiology of NAFLD.

show abstract

“…It thus appeared that it is the increased of adipocytes as liver steatosis -might lead to elevated hs-CRP levels in over-weight patients. C-reactive protein can be act as a marker of steatosis, but not in other liver disease cases (Esther et al, 2015).…”

Section: Resultsmentioning

confidence: 99%

“…The CRP expression in the liver more than in the adipose tissue. The total amount of hs-CRP released in the adipose tissue may be limited by the amount of adipose tissue of the human body (Esther et al, 2015).…”

Section: Resultsmentioning

confidence: 99%

An Essential Role for TGF-β1 and other Clinical Parameters in Non-alcoholic Fatty Liver Disease in Iraqi Patients

Waheed¹,

Shafek²,

Hadi³

2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients

Abstract: This study indicates that it is the accumulation of fat -both in the adipose tissue and in liver steatosis- that leads to increased hs-CRP levels among obese patients. Thus, hs-CRP may be a marker of steatosis, but not of severity of NAFLD, in obese patients.

Cited by 102 publications

References 26 publications

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis

An Essential Role for TGF-β1 and other Clinical Parameters in Non-alcoholic Fatty Liver Disease in Iraqi Patients

Contact Info

Product

Resources

About